OncoSil Medical (ASX:OSL) Cash Receipts from Operating Activities: A$3.96 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:OSL OncoSil Medical Ltd ASX:OSL
73 GF Score
Price A$1.02
GF Value A$1.44
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is OncoSil Medical Cash Receipts from Operating Activities?

OncoSil Medical ASX:OSL +3.57% 73 Cash Receipts from Operating Activities is A$3.96 Mil as of Jun. 2026. GuruFocus rates ASX:OSL with a GF Score™ of 73/100 and a GF Value™ of A$1.44 (Possible Value Trap). The stock has 2 warning signs investors should review.

OncoSil Medical's Cash Receipts from Operating Activities for the six months ended in Jun. 2026 was A$2.80 Mil.

OncoSil Medical's Cash Receipts from Operating Activities for the trailing twelve months (TTM) ended in Jun. 2026 was A$3.96 Mil.

OncoSil Medical Cash Receipts from Operating Activities Related Terms

OncoSil Medical Cash Receipts from Operating Activities Historical Data

* Premium members only.

The historical data trend for OncoSil Medical's Cash Receipts from Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSil Medical Cash Receipts from Operating Activities Chart

OncoSil Medical Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Cash Receipts from Operating Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.10 1.19 1.38 1.81 3.96

OncoSil Medical Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cash Receipts from Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.41 1.40 1.16 2.80
ASX:OSL
73GF Score
OncoSil Medical Ltd ASX:OSL
Cash Receipts from Operating Activities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoSil Medical Cash Receipts from Operating Activities Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

GuruFocus lists following items in "Cash Receipts from Operating Activities" section for non-financial companies:
Receipts from Customers
Receipts from Government Grants
Other Cash Receipts from Operating Activities

Cash Receipts from Operating Activities for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$3.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Receipts from Operating Activities of A$3.96 Mil mean?
OncoSil Medical (ASX:OSL) has a Cash Receipts from Operating Activities of A$3.96 Mil as of Jun. 2026. Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method. View historical data for OncoSil Medical and its competitors.
Is OncoSil Medical's Cash Receipts from Operating Activities too high?
OncoSil Medical's current Cash Receipts from Operating Activities is A$3.96 Mil. Overall, OncoSil Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's Cash Receipts from Operating Activities compare to ABT and SYK?
OncoSil Medical's Cash Receipts from Operating Activities of A$3.96 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Receipts from Operating Activities for a Medical Devices & Instruments company?
A good Cash Receipts from Operating Activities depends on the Medical Devices & Instruments industry context. However, Cash Receipts from Operating Activities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Receipts from Operating Activities mean?
A high Cash Receipts from Operating Activities can signal that a stock is expensive relative to its fundamentals. Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method. View historical data for OncoSil Medical and its competitors. OncoSil Medical's current Cash Receipts from Operating Activities is A$3.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.44, compared to a current price of A$1.02 — trading 29.5% below its estimated fair value. The current Cash Receipts from Operating Activities is A$3.96 Mil. OncoSil Medical's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Receipts from Operating Activities calculated?
Cash Receipts from Operating Activities is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current Cash Receipts from Operating Activities is A$3.96 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoSil Medical (ASX:OSL) Overvalued in 2026?

Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued. The current stock price of A$1.02 is trading 29.5% below its estimated GF Value™ of A$1.44. GuruFocus considers OncoSil Medical to be Possible Value Trap.

Key valuation signals for ASX:OSL:

  • Cash Receipts from Operating Activities: A$3.96 Mil
  • GF Value™: A$1.44 vs. price of A$1.02 (29.5% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoSil Medical Business Description

Address 7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
73GF Score

Get the complete analysis for ASX:OSL

Cash Receipts from Operating Activities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.02
Price
A$1.44
GF Value